Cornelius L Van Gorp

Title: Cornelius L Van Gorp: Innovator in Hematology

Introduction

Cornelius L Van Gorp is a notable inventor in the field of hematology. He has made significant contributions to the understanding and treatment of platelet aggregation and thrombin generation. His work focuses on the combined use of specific agonists and antagonists to improve therapeutic outcomes while minimizing side effects.

Latest Patents

Cornelius L Van Gorp holds a patent titled "Combinations Of Heparin Cofactor Ii Agonist And Platelet Iib/iiia Antagonist, And Uses Thereof." This patent describes a method that combines a heparin cofactor II agonist with a platelet GPIIb/IIIa receptor antagonist. The goal of this combination is to inhibit both platelet aggregation and thrombin generation, which can occur due to disease, injury, or responses to wound repairs. The innovative approach aims to achieve therapeutic benefits while reducing the risk of hemorrhagic side effects, such as prolonged bleeding, and avoiding undesired antigenic responses.

Career Highlights

Cornelius L Van Gorp is associated with Celsus Biopharmaceuticals, Inc., where he continues to advance his research and development efforts. His work has the potential to significantly impact the treatment of conditions related to blood clotting and cardiovascular health.

Collaborations

Cornelius has collaborated with Alan D Cardin, contributing to the development of innovative solutions in the field of biopharmaceuticals.

Conclusion

Cornelius L Van Gorp's contributions to the field of hematology through his innovative patent work demonstrate his commitment to improving patient outcomes. His research continues to pave the way for advancements in the treatment of thrombotic conditions.